tbuckley/cabot-search huggingface dataset:
Can Target-to-Background Ratio Measurement Lead to Detection and Accurate Quantification of Atherosclerosis With FDG PET? Likely Not
Authors: Abass Alavi, Thomas J. Werner, Poul Flemming. Høilund-Carlsen, Mona-Elisabeth Revheim
Journal: Clinical Nuclear Medicine (2022)

The introduction of FDG in 1976 started a new discipline and enhanced the role of molecular imaging in medicine. While the initial intent with this tracer was to determine brain function in a variety of neuropsychiatric disorders, over time, this powerful approach has made a major impact on managing many other diseases and disorders. During the past 2 decades, FDG PET has been used to detect inflammatory lesions in the atherosclerotic plaques and in other settings. However, the suboptimal spatial resolution of PET limits its ability to visualize plaques that are very small in size. Furthermore, this tracer remains in the blood for an extended period and therefore provides suboptimal results. Target-to-background ratio (TBR) has been suggested to correct for this source of error. Unfortunately, TBR values vary substantially, depending on the timing of image acquisition. Delayed imaging at later time points (3-4 hours) may obviate the need for TBR measurement, but it is impractical with conventional PET instruments. Recently, 18F-sodium fluoride (NaF) has been used for detection and quantification of molecular calcification in the plaques. This tracer is highly specific for calcification and is rapidly cleared from the circulation. In addition, global atherosclerotic burden as measured by NaF PET can be determined accurately either in the heart or major arteries throughout the body. Therefore, the role of FDG PET-based TBR measurement for detection and quantification of atherosclerotic plaques is questionable at this time.
MANAGEMENT OF NONFUNCTIONAL PANCREATIC NEUROENDOCRINE TUMORS BY ENDOSCOPIC ULTRASOUND-GUIDED RADIOFREQUENCY ABLATION: A RETROSPECTIVE STUDY IN TWO TERTIARY CENTERS
Authors: M. Marx, S. Godat, F. Caillol, F. Poizat, J.-P. Ratone, C. Pesenti, A. Schoepfer, S. Hoibian, Y. Dahel, M. Giovannini
Journal: Endoscopy (2022)

Aims Recently, there has been growing interest in investigating endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for the management of small nonfunctional pancreatic neuroendocrine tumors (nf pNETs). This study presents a preliminary clinical experience, focusing on procedure-related complications.
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial
Authors: Christopher Elnan Kvistad, Halvor Næss, Bernt H Helleberg, Titto Idicula, Guri Hagberg, Linn Marie Nordby, Kristian N Jenssen, Håkon Tobro, Dag M Rörholt, Kamaljit Kaur, Agnethe Eltoft, Kristin Evensen, Judit Haasz, Guruparan Singaravel, Annette Fromm, Lars Thomassen
Journal: The Lancet Neurology (2022)
ENDOSCOPIC FULL-THICKNESS RESECTION (EFTR) FOR EARLY COLORECTAL CARCINOMA (CRC) – A RETROSPECTIVE ANALYSIS OF 31 CONSECUTIVE CASES
Authors: P. Stathopoulos, M. Zumblick, S. Hoque, T.M. Gress, C. Denkert, U.W. Denzer
Journal: Endoscopy (2022)

Aims EFTR has an emerging role in the resection of early CRC with low-risk histological features. We aimed to access the efficacy, safety and oncologic follow-up of patients with early CRC treated with eFTR.
ENDOSCOPIC REDUCTION OF INTUSSUSCEPTION IN 19 PATIENTS WITH PEUTZ-JEGHERS SYNDROME
Authors: K. Oguro, H. Sakamoto, T. Yano, Y. Funayama, M. Kitamura, S. Miyahara, M. Nagayama, K. Sunada, A. Kawarai Lefor, H. Yamamoto
Journal: Endoscopy (2022)

Aims Intussusception caused by intestinal polyps in patients with Peutz-Jeghers syndrome (PJS) usually requires laparotomy. Several patients who underwent successful endoscopic reduction were reported in the development of double-balloon endoscopy (DBE). The aim of this study is to evaluate the feasibility and safety of endoscopic reduction of intussusception.
EVALUATION OF THE REPRODUCIBILITY OF EACH LOCATION OF STOMACH IN THE NEW GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION TRAINING MODEL
Authors: T. Mitsui, Y. Yoda, H. Sunakawa, K. Takashima, K. Nakajo, T. Murano, T. Kadota, K. Shinmura, H. Ikematsu, T. Yano
Journal: Endoscopy (2022)

Aims Gastric ESD is a highly technical procedure mainly due to the distinctive shape of the tract and diverse lesion locations. We have developed a new gastric ESD training model (G-Master​) with KOTOBUKI Medical (Saitama, Japan) and assessed the reproducibility of the lesion location in the model.
EVOLUTION OF CAUSTIC INJURY OF THE UPPER GASTROINTESTINAL TRACT: ABOUT 38 CASES
Authors: H. Aouroud, J. Rizkou, A. Ait Errami, S. Oubaha, Z. Samlani, K. Krati
Journal: Endoscopy (2022)

Aims The aim of this work is to report our experience of caustic injure of the upper gastrointestinal tract and to analyze the evolution of the lesions.
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy
Authors: Charito Love, Neil B. Desai, Tony Abraham, Kevin P. Banks, Lisa Bodei, Thomas Boike, Richard K. J. Brown, David L. Bushnell, Lorraine E. DeBlanche, Michael M. Dominello, Tony Francis, Erin C. Grady, Robert F. Hobbs, Thomas A. Hope, Jeffrey S. Kempf, Daniel A. Pryma, William Rule, Bital Savir-Baruch, Ila Sethi, Rathan M. Subramaniam, Ying Xiao, Naomi R. Schechter
Journal: Clinical Nuclear Medicine (2022)

This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs) from foregut, midgut, and hindgut. The essential selection criteria include somatostatin receptor-positive GEP-NETs, which are usually inoperable and progressed despite standard therapy. Lu-177 DOTATATE is a radiopharmaceutical with high avidity for somatostatin receptors that are overexpressed by these tumors. This document ensures safe handling of Lu-177 DOTATATE by the authorized users and safe management of affected patients.The document was developed according to the systematic process developed by the American College of Radiology (ACR) and described on the ACR Web site (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards). The PP development was led by 2 ACR Committees on Practice Parameters (Nuclear Medicine and Molecular Imaging and Radiation Oncology) collaboratively with the American College of Nuclear Medicine, American Society of Radiation Oncology, and Society of Nuclear Medicine and Molecular Imaging.The Lu-177 DOTATATE PP reviewed pharmacology, indications, adverse effects, personnel qualifications, and required clinical evaluation before starting the treatment, as well as the recommended posttherapy monitoring, quality assurance, documentation, and appropriate radiation safety instructions provided in written form and explained to the patients.Lu-177 DOTATATE is available for therapy of inoperable and/or advanced GEP-NETs when conventional therapy had failed. It can reduce tumor size, improve symptoms, and increase the progression free survival. The PP document provides clinical guidance for authorized users to assure an appropriate, consistent, and safe practice of Lu-177 DOTATATE.
AUTOMATIC DETECTION AND CLASSIFICATION OF PLEOMORPHIC SMALL BOWEL LESIONS WITH DIFFERENT BLEEDING POTENTIAL USING A CONVOLUTIONAL NEURAL NETWORK: A MULTICENTRIC STUDY
Authors: M. Mascarenhas, J. Afonso, T. Ribeiro, J. Ferreira, P. Andrade, M. Mascarenhas Saraiva, H. Cardoso, G. Macedo
Journal: Endoscopy (2022)

Aims Capsule endoscopy enables the detection of enteric pleomorphic lesions with different bleeding potentials. However, reading CE exams is a time-consuming and monotonous task prone to errors. Convolutional neural networks (CNNs) are highly efficient artificial intelligence tools for image analysis. Our group developed a CNN-based model for detecting and differentiating pleomorphic small bowel lesions with distinct hemorrhagic potential using CE images.
ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN RUPTURED LIVER HYDATID CYST
Authors: S. Elmamouni, M. Borahma, F.Z. Chabib, M. Kadiri, I. Ben Elbarhdadi, F.Z. Ajana
Journal: Endoscopy (2022)

Aims We retrospectively reviewed the effectiveness of endoscopic treatment ofruptured hydatid cyst into intrahepatic bile ducts.
CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma
Authors: Wen Lei, Qian Ye, Yuanyuan Hao, Jie Chen, Yu Huang, Liu Yang, Shibing Wang, Wenbin Qian
Journal: Blood Cancer Journal (2022)

Abstract Immunotherapy with CD19-targeting bispecific T-cell engagers (CD19BiTEs) has demonstrated highly effective killing of cancer cells in patients with precursor acute lymphoblastic leukemia and non-Hodgkin’s lymphomas. However, there are some drawbacks to this therapy, such as toxicity, short half-life in the serum, and immunosuppressive tumor microenvironment that could limit the use of CD19BiTEs in the clinic. Here, we generate an oncolytic vaccinia virus (OVV) encoding a CD19-specific BiTE (OVV-CD19BiTE). We demonstrate that OVV-CD19BiTE’s ability to replicate and induce oncolysis was similar to that of its parental counterpart. Supernatants from OVV-CD19BiTE-infected cells could induce activation and proliferation of human T cells, and the bystander effect of the virus was also demonstrated. In vivo study showed that OVV-CD19BiTE selectively replicated within tumor tissue, and contributed to a more significantly increased percentage of CD3, CD8, and naïve CD8 T subpopulations within tumors in contrast to blinatumomab. More importantly, treatment with OVV-CD19BiTE both in vitro and in vivo resulted in potent antitumor activity in comparison with control OVV or blinatumomab, a first-in-class BiTE, thereby resulting in long-term tumor remissions without relapse. The study provides strong evidence for the therapeutic benefits of CD19-targeting BiTE expression by OVV, and suggests the feasibility of testing the approach in clinical trials.
WHAT IS THE CONTRIBUTION OF COLONOSCOPY IN PATIENTS WITH MELENA AND NORMAL UPPER GASTRO-INTESTINAL ENDOSCOPY ?
Authors: A. Sair, A. Benhamdane, T. Addajou, M. Osman, S. Mrabti, R. Berraida, S. Sentissi, I. Elkoti, F. Rouibaa, A. Benkirane, H. Seddik
Journal: Endoscopy (2022)

Aims The origin of melena is located upstream of the right colon,their etiologies are multiple,ranging from a simple gastric ulcer to a tumor lesion. The first-line examination for melenas is oeso-gastro-duodenal endoscopy, but when it is normal, other endoscopic explorations are necessary, notably total colonoscopy.
Re: Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland. Thulium Fibre Laser Versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.02.027
Authors: Frederic Panthier, Alba Sierra, Olivier Traxer
Journal: European Urology (2022)
60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B
Authors: J. Furlanetto, F. Marmé, C. Thode, V. Nekljudova, Y. Liu, M. Martin Jimenez, T. Reimer, E. Knudsen, C. Denkert, M. Bassy, L-A. Martin, T. Karn, B.V. Sinn, M. Filipitis, M. van Mackelenbergh, P.A. Fasching, V. Müller, E. Stickeler, C. Schem, S. Loibl
Journal: Annals of Oncology (2022)

PENELOPE-B is a phase III study investigating the role of PAL + ET vs placebo + ET in HR+, HER2- early BC pts with high risk of relapse after neoadjuvant chemotherapy (NACT). Invasive disease-free survival was not improved with PAL + ET (Loibl JCO 2021). Estradiol (E2), follicle-stimulating hormone (FSH), anti-Müllerian hormone (AMH) values might be influenced by post-NACT PAL. Changes in hormones for pts treated with CDK4/6 inhibitors + ET are not well explored. 616 pts were premenopausal at baseline (BL, investigator-defined). Pts with serum samples at BL and at least before cycle (C) 7 or at end of treatment (EOT) were considered (N=576). 576 pts provided blood samples at BL, 526 before C7, 541 at EOT. Centrally assessed FSH>12.4 IU/l and E2<52.2 ng/L were defined as postmenopausal; fertile level of AMH as ≥0.22 ng/mL (central lab cut-offs). Analysed subgroups were pre- vs postmenopausal FSH/E2 at BL, age ≤40 vs >40 yrs, gonadotropin-releasing hormone analogue (GnRHa) use vs no. Median age was 43 (19-56) yrs; 46.8% pts had BMI <25, 53.2% ≥25. Hormone values are shown below. At BL, 41.6% of pts in the placebo vs 41.3% in the PAL arm had premenopausal hormone levels. Of these, 9.1 vs 13.5% (p=0.387) had postmenopausal hormone levels at C7. In pts ≤40 yrs 29.2 vs 29.5% at BL (p=1.000), 18.1 vs 23.4% at C7 (p=0.472) had postmenopausal values. More pts >40 yrs (BL 75.3%, C7 69.8%) vs ≤40 yrs (29.4, 20.7%) and without GnRHa (80.3, 72.2%) vs with (15.9, 12.1%) had postmenopausal hormone levels. Median AMH was under the detection limit at all time points. At BL 91.8 vs 93.6% had non-fertile levels of AMH (p=0.426), 94.4 vs 96.5% at C7 (p=0.298), without difference in subgroups. EOT analysis will be presented at the meeting.Table: 60MOMedian, IQRFSH IU/lE2 ng/LPALPp-valuePALPp-valueAll premenopausal at BL (investigator-defined)BL35.67.1-55.532.56.3-54.20.407dt2.5-13.0dt2.5-14.00.242C724.15.5-37.718.45.1-34.30.157dt2.5-10.0dt2.5-10.00.726Premenopausal E2 and FSH at BLBL5.63.2-11.25.53.1-9.00.5716.02.5-105.07.02.5-125.00.768C74.82.5-14.44.62.3-8.80.258dtdt-14.0dtdt-13.00.940≤40 yrsBL10.63.8-46.97.64.4-41.50.8788.0dt-74.07.5dt-55.00.910C78.02.9-32.15.22.7-16.90.1505.0dt-55.0dtdt-22.00.448GnRHa use, BLBL5.13.1-10.65.03.1-9.00.731dtdt-8.0dtdt-9.00.792C73.52.2-7.04.32.2-8.00.489dtdt-5.0dtdt-6.00.574Detectable threshold, dt: E2=5 ng/L; P, placebo Open table in a new tab Detectable threshold, dt: E2=5 ng/L; P, placebo PAL does not influence FSH, E2 and the ovarian reserve significantly when added to ET after NACT.
ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY IN THE MANAGEMENT OF IATROGENIC BILE DUCT INJURY
Authors: I. Tishkov, P. Karagyozov, I. Jecheva
Journal: Endoscopy (2022)

Aims The aim of this study was to assess the role of endoscopic retrograde cholangiopancreatography ( ERCP) in the management of iatrogenic bile duct injuries.
DETECTING LYNCH SYNDROME IN A NATIONAL COLORECTAL CANCER SCREENING PROGRAMME
Authors: J. Cudmore, L. Kumar, G. Cullen, G. Horgan, J. Aird, K. Sheehan, J. Leyden
Journal: Endoscopy (2022)

Aims Lynch Syndrome(LS) is the most common cause of hereditary colorectal cancer(CRC) accounting for 2-4% of all CRCs. It is characterised by pathogenic variants in mismatch repair(MMR) genes. Many people are unaware of their diagnosis. Universal testing of all CRCs has been recommended to address this. The aim was to determine the proportion of CRCs tested for LS at two screening sites of the Irish national CRC screening service, BowelScreen, and to examine the outcomes of testing.
EFFICACY, SAFETY AND CLINICAL OUTCOMES OF ENDOSCOPIC MUCOSAL RESECTION (EMR) AND ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) IN PATIENTS WITH GASTRIC AND DUODENAL NEUROENDOCRINE TUMORS
Authors: M. Giunta, D. Ravizza, I. Bravi, G. de Roberto, P. Soru, C. Crosta, C. Trovato, G. Fiori
Journal: Endoscopy (2022)

Aims We aim to evaluate efficacy, safety and clinical outcomes of EMR and ESD for gastroduodenal neuroendocrine tumors (gNETs and dNETs).
INTRODUCTION OF A 3RD GENERATION FNB NEEDLE IN COMMUNITY HOSPITAL PRACTICE INCREASES QUALITY AND YIELD OF EUS-GUIDED TA OF SOLID PANCREATIC LESIONS
Authors: H.M. Schutz, M.-P.G. Anten, I. Leeuwenburgh, K.J. Hoogduin, M.J. Bruno, L.M. van Driel, R. Quispel
Journal: Endoscopy (2022)

Aims The ASGE has formulated three quality indicators (KPI) for EUS-guided TA according to a specific performance target (PT): rate of adequate sample (PT 85%), diagnostic yield of malignancy (PT 70%) and sensitivity for malignancy (PT 85%). Feedback on performance is provided to collaborating centers of the Dutch Quality in endosonography team (QUEST) annually using these KPIs. In this study we report the effect of implementation of a 3rd generation FNB needle in one of the collaborating community hospitals on KPIs.
ESD OF A LARGE CECAL POLYP INVOLVING THE ILEOCECAL VALVE AND THE TERMINAL ILEUM
Authors: G. Mavrogenis, F. Bazerbachi, D. Mpalomenos, I. Tsevgas, D. Zachariadis
Journal: Endoscopy (2022)

Aim An 83-year-old man was referred for endoscopic resection of a large cecal polyp that involved the ileocecal valve and extended 1 cm upstream in the terminal ileum.
ENDOSCOPIC OR SURGICAL MYOTOMY FOR ACHALASIA: AN OBJECTIVE PERSPECTIVE, SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: A.S.T. Kum, D. Turiani Hourneaux de Moura, E. Silvino Do Monte Junior, I. Mendonça Proença, A. De Morais Bestetti, J.G. Ribeiro Jordao Sasso, W. Marques Bernardo, E. Turiani Hourneaux De Moura, I. Braga Ribeiro, E. Guimaraes Hourneaux De Moura
Journal: Endoscopy (2022)

Aims With the advent of the Lyon consensus, a modern evaluation of reflux, we aim to evaluate the literature comparing POEM to Heller myotomy (HM) for the treatment of achalasia with objective measurements.
ANTI-REFLUX VERSUS CONVENTIONAL SELF-EXPANDING METAL STENTS (SEMS) IN THE PALLIATION OF ADVANCED ESOPHAGEAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS
Authors: J.G. Ribeiro Jordão Sasso, I. Mendonça Proença, E. Silvino do Monte Junior, S.A. Sánchez-Luna, I. Braga Ribeiro, A. Moraes Bestetti, A. So Taa Kum, D. Turiani Hourneaux de Moura, M. Eduardo Lera dos Santos, R. Silva de Paula Rocha, W. Marques Bernardo, E. Guimarães Hourneaux de Moura
Journal: Endoscopy (2022)

Aims Conventional self-expanding metal stents (SEMS-NV) are an effective palliative therapy to reduce dysphagia and improve the patient’s nutritional status. Gastroesophageal reflux disease (GERD) is a common adverse event after the use of SEMS, and it has been proposed that valved SEMS (SEMS-V) could improve the quality of life of patients. This is a systematic review and meta-analysis that includes only randomized clinical trials (RCTs) and that aimed at comparing SEMS-V versus SEMS-NV in the palliation of advanced esophageal cancer.
Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta‐analysis
Authors: Robert A. McCutcheon, Toby Pillinger, Orestis Efthimiou, Marta Maslej, Benoit H. Mulsant, Allan H. Young, Andrea Cipriani, Oliver D. Howes
Journal: World Psychiatry (2022)

It is common experience for practising psychiatrists that individuals with schizophrenia vary markedly in their symptomatic response to antipsychotic medication. What is not clear, however, is whether this variation reflects variability of medication‐specific effects (also called “treatment effect heterogeneity”), as opposed to variability of non‐specific effects such as natural symptom fluctuation or placebo response. Previous meta‐analyses found no evidence of treatment effect heterogeneity, suggesting that a “one size fits all” approach may be appropriate and that efforts at developing personalized treatment strategies for schizophrenia are unlikely to succeed. Recent advances indicate, however, that earlier approaches may have been unable to accurately quantify treatment effect heterogeneity due to their neglect of a key parameter: the correlation between placebo response and medication‐specific effects. In the present paper, we address this shortcoming by using individual patient data and study‐level data to estimate that correlation and quantitatively characterize antipsychotic treatment effect heterogeneity in schizophrenia. Individual patient data (on 384 individuals who were administered antipsychotic treatment and 88 who received placebo) were obtained from the Yale University Open Data Access (YODA) database. ﻿Study‐level data were obtained from a meta‐analysis of 66 clinical trials including 17,202 patients. Both individual patient and study‐level analyses yielded a negative correlation between placebo response and treatment effect for the total score on the Positive and Negative Syndrome Scale (PANSS) (ρ=–0.32, p=0.002 and ρ=–0.39, p&lt;0.001, respectively). Using the most conservative of these estimates, a meta‐analysis of treatment effect heterogeneity provided evidence of a marked variability in antipsychotic‐specific effects between individuals with schizophrenia, with the top quartile of patients experiencing beneficial treatment effects of 17.7 points or more on the PANSS total score, while the bottom quartile presented a detrimental effect of treatment relative to placebo. This evidence of clinically meaningful treatment effect heterogeneity suggests that efforts to personalize antipsychotic treatment of schizophrenia have potential for success.
LOCAL INJECTION OF TRIAMCINOLONE ACETONIDE WITH SELECTED ADDED ORAL STEROID THERAPY AFTER EXTENSIVE ESOPHAGEAL ESD TO PREVENT STRICTURE: A PROSPECTIVE VALIDATION PROTOCOL IN WESTERN COUNTRIES
Authors: G. Englebert, D. Carpentier, A.-M. Bucalau, L. Verset, P. Demetter, P. Eisendrath, J. Devière, A. Lemmers
Journal: Endoscopy (2022)

Aims Oral steroid is usually administered in Western countries to prevent post-ESD esophageal stricture after extensive resection. A single local injection of triamcinolone acetonide (TA) at the end of ESD has been demonstrated to be effective for resections comprising 50 to 90% of circumference in Japan.
110P An in-depth analysis of pathology results of surgical specimen and biopsies performed after NST in an attempt to identify patients with pCR: Time to reconsider the omission of surgery?
Authors: A.K.E. van Hemert, F.H. van Duijnhoven, A.A. van Loevezijn, C.E. Loo, T. Wiersma, G.S. Sonke, E. Groen, M.J.T.F.D. Vrancken Peeters
Journal: Annals of Oncology (2022)
EARLY CAPSULE ENDOSCOPY AND DEVICE-ASSISTED ENTEROSCOPY IN OVERT BLEEDING: A SYSTEMATIC REVIEW WITH META-ANALYSIS
Authors: M.M. Estevinho, R. Pinho, C. Fernandes, A. Rodrigues, A. Ponte, A.C. Gomes, E. Afecto, J. Correia, T. Freitas
Journal: Endoscopy (2022)

Aims The best timing for small bowel capsule endoscopy (SBCE) and device-assisted enteroscopy (DAE) for the management of obscure gastrointestinal bleeding (OGIB) remains unknown. This meta-analysis aimed to compare, for the first time, diagnostic and therapeutic yields, detection of active bleeding and vascular lesions, rebleeding, and mortality of “early” versus “non-early” SBCE and DAE.
COMPARISON BETWEEN ENDOSCOPIC ULTRASOUND-GUIDED FINE-NEEDLE BIOPSY AND BITE-ON-BITE JUMBO BIOPSY FOR SAMPLING OF SUBEPITHELIAL LESIONS
Authors: A. Facciorusso, S.F. Crinò, D. Ramai, A. Ofosu, N. Muscatiello, B. Mangiavillano, L. Lamonaca, A. Lisotti, P. Fusaroli, P. Gkolfakis, E. Stasi, J. Samanta, J. Dhar, C. Cotsoglou, J. Londoño Castillo, F. Antonini
Journal: Endoscopy (2022)

Aims A direct comparison between endoscopic ultrasound (EUS) fine-needle biopsy (FNB) and current endoscopic biopsy techniques in patients with subepithelial lesions (SELs) is still lacking. Aim of this multicenter study was to compare the diagnostic performance and safety profile between EUS-FNB and bite-on-bite jumbo biopsy.
RISK FACTORS FOR COLONIC SESSILE SERRATED LESIONS
Authors: C. Nascimento, J. Revés, B. Morão, C. Frias Gomes, L. Glória, A. Ferreira
Journal: Endoscopy (2022)

Aims Sessile serrated lesions (SSL) are pre-malignant colorectal lesions thought to be precursors to 20-35% of colorectal cancer (CRC). However, little is known about their epidemiology. Our aim was to identify risk factors for SSL.